Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Top Cited Papers
Open Access
- 8 December 2020
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 397 (10269), 99-111
- https://doi.org/10.1016/s0140-6736(20)32661-1
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trialThe Lancet, 2020
- Ethnicity and clinical outcomes in COVID-19: A systematic review and meta-analysisEClinicalMedicine, 2020
- COVID-19 in critical care: epidemiology of the first epidemic wave across England, Wales and Northern IrelandIntensive Care Medicine, 2020
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trialThe Lancet, 2020
- Vaccine Efficacy Needed for a COVID-19 Coronavirus Vaccine to Prevent or Stop an Epidemic as the Sole InterventionAmerican Journal of Preventive Medicine, 2020
- A minimal common outcome measure set for COVID-19 clinical researchThe Lancet Infectious Diseases, 2020
- Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based studyThe Lancet, 2020
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort studyThe Lancet, 2020
- Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trialBMJ, 2015
- A Modified Poisson Regression Approach to Prospective Studies with Binary DataAmerican Journal of Epidemiology, 2004